Search

Roche Holding AG

Closed

SectorHealthcare

305.6 0.92

Overview

Share price change

24h

Current

Min

299.2

Max

308

Key metrics

By Trading Economics

Income

1.7B

3.7B

Sales

-15B

16B

P/E

Sector Avg

22.865

35.739

Dividend yield

3.62

Profit margin

23.266

Employees

103,249

EBITDA

547M

6.5B

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.62%

3.08%

Market Stats

By TradingEconomics

Market Cap

-368M

205B

Previous open

304.68

Previous close

305.6

News Sentiment

By Acuity

12%

88%

10 / 371 Ranking in Healthcare

Roche Holding AG Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 paź 2025, 08:54 UTC

Major Market Movers

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18 wrz 2025, 14:01 UTC

Acquisitions, Mergers, Takeovers

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

18 wrz 2025, 10:05 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

89bio Shares Soar Premarket on Takeover by Roche

18 wrz 2025, 10:04 UTC

Acquisitions, Mergers, Takeovers

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

18 wrz 2025, 05:37 UTC

Acquisitions, Mergers, Takeovers

Roche to Buy 89bio for Up to $3.5 Billion

24 lip 2025, 15:09 UTC

Earnings

Roche Weighs Selling Drugs Directly to Patients in Bid to Lower U.S. Prices -- Update

24 lip 2025, 05:36 UTC

Earnings

Roche Backs 2025 Views After Strong Sales of Key Drugs

1 paź 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

1 paź 2025, 09:05 UTC

Hot Stocks

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

18 wrz 2025, 14:12 UTC

Acquisitions, Mergers, Takeovers

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

18 wrz 2025, 07:37 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

18 wrz 2025, 05:09 UTC

Acquisitions, Mergers, Takeovers

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

18 wrz 2025, 05:06 UTC

Acquisitions, Mergers, Takeovers

Roche: Deal Is Expected to Close in 4Q

18 wrz 2025, 05:06 UTC

Acquisitions, Mergers, Takeovers

Roche: Deal Enhanc Portfolio in Cardiovascular, Renal, Metabolic Diseases

18 wrz 2025, 05:05 UTC

Acquisitions, Mergers, Takeovers

Roche: MASH Is One of Most Prevalent Comorbidities of Obesity

18 wrz 2025, 05:05 UTC

Acquisitions, Mergers, Takeovers

Roche: 89bio Developing Potential Treatment for Metabolic Dysfunction-Associated Steatohepatitis

18 wrz 2025, 05:04 UTC

Acquisitions, Mergers, Takeovers

Roche to Buy 89bio for $14.50 a Share in Cash, Contingent Value Right of Up to $6 a Share

18 wrz 2025, 05:03 UTC

Acquisitions, Mergers, Takeovers

Roche: Total Deal Value Is Up to $3.5B

18 wrz 2025, 05:02 UTC

Acquisitions, Mergers, Takeovers

Roche to Buy 89bio

18 wrz 2025, 05:02 UTC

Acquisitions, Mergers, Takeovers

Roche Enters Into Deal to Buy 89bio

8 sie 2025, 10:51 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

8 sie 2025, 07:39 UTC

Market Talk
Earnings

Roche Could Reach Peak Earnings Growth This Year -- Market Talk

5 sie 2025, 10:40 UTC

Market Talk

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

24 lip 2025, 06:52 UTC

Market Talk
Earnings

Roche Looks Confident in a Tricky Environment -- Market Talk

24 lip 2025, 05:05 UTC

Earnings

Roche Backs 2025 View

24 lip 2025, 05:05 UTC

Earnings

Correct: Roche 1H Diagnostics Sales Down 3%, Reported

24 lip 2025, 05:04 UTC

Earnings

Correct: Roche 1H Sales Rose 4% On Year , Reported

24 lip 2025, 05:04 UTC

Earnings

Roche 1H Net Pft Was Seen at CHF8.4B

24 lip 2025, 05:04 UTC

Earnings

Roche 1H Net Pft CHF7.8B

24 lip 2025, 05:03 UTC

Earnings

Roche 1H Oper Pft CHF12.0B

Roche Holding AG Forecast

Sentiment

By Acuity

10 / 371 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat